This summer, Stealth BioTherapeutics (Stealth BT) shared preliminary positive data from the MMPOWER study. The study purpose was to evaluate safety and efficacy of elamipretide (previously known as Bendavia) in adults with primary mitochondrialRelated to the mitochondria. myopathy and genetically confirmed mitochondrial disease. Mitochondrial myopathy is primarily characterized by muscle weakness, fatigueThe overall feeling of tiredness or lack of energy. It is not the same as simply feeling drowsy or sleepy. Being fatigued means having no motivation or energy., and exercise intolerance. Patients with genetically confirmed mitochondrial disorders may also experience multi-system organ involvement and myriad of complications related to the body’s inability to adequately generate energy (ATP) at the cellular level.
The MMPOWER trial measured changes in the participant’s ability to complete a six-Minute walk test, a performance-based measure of functional exercise capacity.
Join us for a collaborative presentation hosted by MitoAction, the United Mitochondrial Disease Foundation, the Foundation for Mitochondrial Medicine, with Stealth BT to learn more about the results from the MMPOWER trial, and information about the planned Phase 3 clinical trial. This special presentation is intended to educate and inform patients, parents, caregivers, family members, and others involved in the daily lives of adults and children with mitochondrial disease.
